Discovery of potent inhibitors of the lysophospholipase autotaxin.
Authors
Shah, PCheasty, A
Foxton, C
Raynham, T
Farooq, M
Gutierrez, I
Lejeune, A
Pritchard, M
Turnbull, A
Pang, L
Owen, P
Boyd, S
Stowell, Alexandra I J
Jordan, Allan M
Hamilton, Niall M
Hitchin, James R
Stockley, M
MacDonald, E
Quesada, M
Trivier, E
Skeete, J
Ovaa, H
Moolenaar, W
Ryder, H
Affiliation
Cancer Research Technology, Discovery Laboratories, Babraham Research Campus, Cambridge CB22 3AT, UKIssue Date
2016-10-14
Metadata
Show full item recordAbstract
The autotoxin-lysophosphatidic acid (ATX-LPA) axis has been implicated in several disease conditions including inflammation, fibrosis and cancer. This makes ATX an attractive drug target and its inhibition may lead to useful therapeutic agents. Through a high throughput screen (HTS) we identified a series of small molecule inhibitors of ATX which have subsequently been optimized for potency, selectivity and developability properties. This has delivered drug-like compounds such as 9v (CRT0273750) which modulate LPA levels in plasma and are suitable for in vivo studies. X-ray crystallography has revealed that these compounds have an unexpected binding mode in that they do not interact with the active site zinc ions but instead occupy the hydrophobic LPC pocket extending from the active of ATX together with the occupying the LPA 'exit' channel.Citation
Discovery of potent inhibitors of the lysophospholipase autotaxin. 2016 Bioorg. Med. Chem. Lett.Journal
Bioorganic & Medicinal Chemistry LettersDOI
10.1016/j.bmcl.2016.10.036PubMed ID
27780639Type
ArticleISSN
1464-3405ae974a485f413a2113503eed53cd6c53
10.1016/j.bmcl.2016.10.036
Scopus Count
Collections
Related articles
- Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
- Authors: Joncour A, Desroy N, Housseman C, Bock X, Bienvenu N, Cherel L, Labeguere V, Peixoto C, Annoot D, Lepissier L, Heiermann J, Hengeveld WJ, Pilzak G, Monjardet A, Wakselman E, Roncoroni V, Le Tallec S, Galien R, David C, Vandervoort N, Christophe T, Conrath K, Jans M, Wohlkonig A, Soror S, Steyaert J, Touitou R, Fleury D, Vercheval L, Mollat P, Triballeau N, van der Aar E, Brys R, Heckmann B
- Issue date: 2017 Sep 14
- Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.
- Authors: Ragle LE, Palanisamy DJ, Joe MJ, Stein RS, Norman DD, Tigyi G, Baker DL, Parrill AL
- Issue date: 2016 Oct 1
- Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.
- Authors: Fells JI, Lee SC, Fujiwara Y, Norman DD, Lim KG, Tsukahara R, Liu J, Patil R, Miller DD, Kirby RJ, Nelson S, Seibel W, Papoian R, Parrill AL, Baker DL, Bittman R, Tigyi G
- Issue date: 2013 Sep
- Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
- Authors: Black KE, Berdyshev E, Bain G, Castelino FV, Shea BS, Probst CK, Fontaine BA, Bronova I, Goulet L, Lagares D, Ahluwalia N, Knipe RS, Natarajan V, Tager AM
- Issue date: 2016 Jun
- Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
- Authors: Gotoh M, Fujiwara Y, Yue J, Liu J, Lee S, Fells J, Uchiyama A, Murakami-Murofushi K, Kennel S, Wall J, Patil R, Gupte R, Balazs L, Miller DD, Tigyi GJ
- Issue date: 2012 Feb